The Treatment of Femoropopliteal In-Stent Restenosis Back to the Future⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. by Laird, John R. & Yeo, Khung Keong
Journal of the American College of Cardiology Vol. 59, No. 1, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.037EDITORIAL COMMENT
The Treatment
of Femoropopliteal
In-Stent Restenosis
Back to the Future*
John R. Laird, MD,† Khung Keong Yeo, MD†‡
Sacramento, California; and Singapore, Singapore
Femoropopliteal in-stent restenosis (ISR) remains one of
the most frustrating problems for the endovascular special-
ist. It is relatively common, occurring in 18% to 40% of
patients within the first year after femoropopliteal artery
stenting (1,2). Femoropopliteal ISR is even more common
after stenting of longer lesions (15 cm) and may occur in
association with femoropopliteal stent fracture (3). Despite
the frequent occurrence of femoropopliteal ISR in clinical
practice, there are few data available regarding the effective-
ness of endovascular interventions for this condition (3–6).
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Experience to date suggests that restenotic lesions can be
treated with high immediate procedural success, but durable
long-term patency remains elusive. Dick et al. (4) compared
balloon angioplasty to cutting balloon angioplasty in 40
patients with femoropopliteal ISR and showed that while
technical success was achieved in all patients, restenosis rates
at 6 months were high in both treatment groups (65% and
73%, respectively). Debulking strategies (excimer laser,
excisional atherectomy) have been employed, but there are
limited data regarding the effectiveness of these approaches
to ISR. Zeller et al. (5) evaluated the effectiveness of
excisional atherectomy for the treatment of femoropopliteal
ISR and found a 1-year restenosis rate of 46%. In our own
experience involving a combination of modalities for the
treatment of femoropopliteal ISR, restenosis at 1 year
occurred in 52.4% of cases (6).
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to disclose.Coronary ISR in the pre–drug-eluting stent (DES) era
was a similarly vexing problem. Recurrence rates as high as
42% to 75% were seen after balloon angioplasty of diffuse
ISR lesions (7,8). Atheroablative devices were used in an
attempt to improve outcomes with mixed results (9,10).
Mehran et al. (11) at the Washington Hospital Center
devised a classification system for coronary ISR lesions in
which pattern I was focal (10 mm in length), pattern II
was diffuse intrastent (10 mm within the stent), pattern
III was diffuse proliferative (10 mm extending outside the
stent edges), and pattern IV was total occlusion (11).
Higher grades of ISR were shown to be independently
associated with recurrent ISR events. They employed rig-
orous methodology, which included the use of intravascular
ultrasound to demonstrate that angiographic assessment of
ISR grade was accurate. This angiographic classification
scheme ultimately proved useful as a prognostic tool and
helped with early patient triage and interventional device
selection.
In this issue of the Journal, Tosaka et al. (12) report on a
retrospective series of 133 patients with femoropopliteal
ISR treated at several centers in Japan. This represents the
largest published series of patients treated for femoropopli-
teal ISR. The authors propose a new classification system
for femoropopliteal ISR based on lesion length and the
presence of in-stent occlusion. Class I (focal) lesions were
defined as restenotic lesions 50 mm, class II (diffuse)
lesions were 50 mm in length, and class III lesions were
complete in-stent occlusions. Each lesion class was fairly
equally represented in this cohort. Treatment consisted of
balloon angioplasty alone without the use of any debulking
devices or stenting. The authors showed that balloon
angioplasty for long ISR lesions (class II) was associated
with similar outcomes when compared to the treatment of
shorter lesions (class I). Recurrent ISR occurred in 49.9% of
class I lesions compared to 53.3% of class II lesions at 2
years. Conversely, the treatment of class III ISR lesions
(in-stent occlusion) was associated with worse outcomes,
with a high rate of recurrent ISR and occlusion (84.8% and
64.6%, respectively) at 2 years. Class III ISR and reference
vessel diameter were the only independent predictors of
recurrent ISR or reocclusion. While the similar outcomes
for patients with focal or diffuse ISR is surprising, the poor
outcomes after treatment of class III ISR is consistent with
previous coronary ISR data and point to the lack of an
effective long-term endovascular solution for this problem.
There are a number of limitations to this study that need
to be addressed. The retrospective nature of the study and
lack of a control group limit any conclusions that can be
made regarding the optimal approach to femoropopliteal
ISR. The relevance of these data in contemporary practice is
somewhat limited in that only balloon angioplasty was used
to treat ISR in this study. In Europe and other countries
outside of the United States, the availability of drug-eluting
balloons (DEB) and DES has changed the paradigm for the
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contemporary treatment of femoropopliteal ISR may in-
clude debulking therapies (excimer laser, excisional, or
rotational atherectomy), cutting or scoring balloons, repeat
stenting, or the use of self-expanding stent grafts. It is also
important to ask whether the classification system proposed
by Tosaka et al. (12) is clinically useful. The ultimate
determinant of usefulness is whether this lesion classifica-
tion is prognostically important and influences the choice of
therapy. Although the poor results of balloon angioplasty
for type III lesions clearly highlight the need for an
alternative treatment strategy, the distinction between type
I and type II lesions has limited utility. The conclusion one
might draw from this study is that balloon angioplasty
would be equally effective for ISR lesions (nonocclusive) no
matter what the length, but that does not reflect clinical
reality. The use of a 50-mm cutoff is somewhat arbitrary and
the choice of such a short lesion length as the cutoff point
between focal and diffuse is not optimal for a vascular bed in
which long segment stenting (200 mm stented length) is
common.
Drug-eluting balloons have proven effective for the treat-
ment of coronary ISR (13) and femoropopliteal disease
(14,15), and they hold promise for the treatment of femo-
ropopliteal ISR. Although initial randomized trials of DEB
for femoropopliteal disease included only a small number of
patients with ISR (14,15), dedicated trials of DEB for
femoropopliteal ISR are ongoing in Europe. The largest
experience to date with drug-eluting technology for femo-
ropopliteal ISR comes from the Zilver PTX multicenter
registry. In this single-arm, real-world registry, 818 lesions
in 718 patients were treated with the paclitaxel-eluting
Zilver stent (Cook Medical, Bloomingdale, Indiana). This
registry included a subset of 142 ISR lesions (16). Freedom
from target lesion revascularization at 12 months and 24
months was 78% and 69%, respectively, for ISR lesions.
These findings appear promising; however, final conclusions
await publication of the complete data set.
Given the paucity of data regarding therapeutic options
and outcomes for patients with femoropopliteal ISR, To-
saka et al. (12) are to be congratulated for their contribution
of this large case series to the literature. Their results
highlight the inadequacy of balloon angioplasty for the
treatment of femoropopliteal ISR, particularly for in-stent
occlusion. While there are limitations to their proposed
classification scheme for femoropopliteal ISR, it is a prom-
ising first step toward a better understanding of outcomes
after treatment of this challenging condition. More work
and research will be required before we can expect a more
durable long-term endovascular solution to femoropopliteal
ISR. Both DEB and DES hold much promise, and we
eagerly look forward to a future in which ISR occurs with iless frequency, and when it does occur, we hope more
effective and durable treatment strategies are available.
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